Ryota Kawai

Mr. Ryota Kawai

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in The Journal of Toxicological Sciences
Verified
Journal Article
Open access
PDF file
RKRyota Kawai
Ryota Kawai
TATetsuo Aida
Tetsuo Aida
HHHiroyuki Hattori
Hiroyuki Hattori
TFTadashi Furukawa
Tadashi Furukawa
KMKazuhiko Mori
Kazuhiko Mori
TKTeruo Kawada
Teruo Kawada
T-cell dependent antibody response (TDAR) incorporating both primary and secondary responses to keyhole limpet hemocyanin (KLH) in canine models have not yet been fully understood. To develop a practical dog TDAR model, we characterized primary and secondary antibody responses by intravenous or intramuscular immunization of KLH twice at intervals of 8 days during a 28-day course of study. Primary immunization with KLH by both routes induced a maximum IgM response on 6 to 8 days after the treatment, whereas the IgG response started 6 to 8 days after the treatment with relatively low levels. Remarkable increases in anti-KLH IgG levels (about 10-times compared with the primary response) were produced 5 to 7 days after the secondary KLH immunization by both routes. These results indicate that IgM-predominant and IgG-predominant responses were respectively induced by the primary and secondary immunization. Furthermore, the intravenous route showed higher baseline titers of primary and secondary anti-KLH IgM responses, suggesting that intravenous immunization of KLH might be a more suitable method for immunotoxicity evaluation. No remarkable inter-individual variability was noted in our canine models. Treatment with cyclophosphamide at 2 mg/kg/day for a consecutive 28 days significantly suppressed primary and secondary anti-KLH IgM and IgG responses induced by KLH injection on Days 15 and 23 of CPA treatment. These results demonstrate that these experimental designs could provide valuable information about the influence on both the primary and secondary humoral immune responses in dogs when exposed to potential immunomodulatory drugs.

1 August 2024 in Mycoses
Verified
Journal Article
Open access
WIWaki Imoto
Waki Imoto
YIYasutaka Ihara
Yasutaka Ihara
TITakumi Imai
Takumi Imai
RKRyota Kawai
Ryota Kawai
KYKoichi Yamada
Koichi Yamada
HKHiroshi Kakeya
Hiroshi Kakeya
Background: Coronavirus disease 2019 (COVID‐19)‐associated pulmonary aspergillosis (CAPA) is one of the noticeable complications of COVID‐19 and its incidence varies widely. In Japan, research on the incidence, risk factors and mortality associated with CAPA is limited.Objectives: This study aimed to explore the incidence and potential risk factors for CAPA in patients with severe or critical COVID‐19 and evaluate the relationship between CAPA and mortality of patients with severe or critical COVID‐19.Methods: We investigated the incidence of CAPA in patients with severe and critical COVID‐19 using administrative claims data from acute care hospitals in Japan. We employed multivariable regression models to explore potential risk factors for CAPA and their contribution to mortality in patients with severe and critical COVID‐19.Results: The incidence of CAPA was 0.4%–2.7% in 33,136 patients with severe to critical COVID‐19. Age, male sex, chronic lung disease, steroids, immunosuppressants, intensive care unit admission, blood transfusion and dialysis were potential risk factors for CAPA in patients with severe to critical COVID‐19. CAPA was an independent factor associated with mortality.Conclusions: CAPA is a serious complication in patients with severe and critical COVID‐19 and may increase mortality.

2 May 2024 in Rheumatology
Verified
Journal Article
Closed access
PDF file
KYKatsuyuki Yoshida
Katsuyuki Yoshida
STSoshi Takahashi
Soshi Takahashi
RKRyota Kawai
Ryota Kawai
TSToshiharu Saito
Toshiharu Saito
SHSaori Hatachi
Saori Hatachi
SKShunichi Kumagai
Shunichi Kumagai
This study aimed to establish a screening model for differentiating anti-synthetase syndrome (ASS) from other ANA-associated rheumatic diseases (AARDs) using a combination of cytoplasmic and non-cytoplasmic ANA (ncANA) patterns. : This retrospective observational study included patients with AARDs such as SLE, SSc, SS, MCTD and PM/DM who underwent ANA screening between April 2012 and December 2021. Variables included age, sex, ANA patterns (Cytoplasmic and ncANA) and titres. Logistic regression analysis of Cytoplasmic and ncANA patterns was performed to differentiate ASS from other AARDs. : The 981 diagnosed cases of AARDs consisted of SS (n = 451), SSc (n = 264), SLE (n = 201), PM/DM (n = 104), MCTD (n = 52) and ASS, including PM/DM (n = 64). Of these, 155 patients had ≥2 overlapping diseases; however, there was no overlap between AARDs and ASS. ASS is more likely to occur when the cytoplasmic titre is positive and the ncANA <320. Receiver operating characteristic analysis of the Cytoplasmic and ncANA range revealed an area under the receiver operating characteristic curve of 0.885 (95% CI: 0.844–0.927). : It is important to detect cytoplasmic patterns as an ANA screening test for ASS diagnosis, even if the titre is low. Additionally, combining the cytoplasmic and ncANA patterns yields more accurate ASS screening results.

1 May 2021 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
HYHiroshi Yoshida
Hiroshi Yoshida
TSTetsuo Suzawa
Tetsuo Suzawa
YSYo Shibata
Yo Shibata
MTMasahiro Takahashi
Masahiro Takahashi
RKRyota Kawai
Ryota Kawai
RKRyutaro Kamijo
Ryutaro Kamijo


29 March 2025 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
WIWaki Imoto
Waki Imoto
YIYasutaka Ihara
Yasutaka Ihara
TBTsubasa Bito
Tsubasa Bito
RKRyota Kawai
Ryota Kawai
HNHiroki Namikawa
Hiroki Namikawa
HKHiroshi Kakeya
Hiroshi Kakeya